Scinovex
article Open AccessTop 1% cited

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

New England Journal of Medicine · 2020 · Vol. 383(27) · pp. 2603–2615
Fernando P. PolackStephen J. ThomasNicholas KitchinJudith AbsalonAlejandra GurtmanStephen LockhartJohn L. PerezGonzalo Pérez MarcEdson Duarte MoreiraCristiano A. F. ZerbiniRuth BaileyKena A. SwansonSatrajit RoychoudhuryKenneth KouryPing LiWarren V. KalinaDavid CooperRobert W. FrenckLaura L HammittÖzlem TüreciHaylene NellAxel SchaeferSerhat ÜnalDina B TresnanSusan MatherPhilip R. DormitzerUğur ŞahinKathrin U. JansenWilliam C. Gruber

Abstract

A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).

SARS-CoV-2 and COVID-19 ResearchViral gastroenteritis research and epidemiologyViral Infections and Immunology ResearchCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakVirologyBusinessMedicineOutbreakInternal medicineInfectious disease (medical specialty)

MeSH terms

COVID-19SARS-CoV-2COVID-19 VaccinesmRNA VaccinesBNT162 VaccineAdolescentAdultAgedFatigueFemaleHeadacheHumansImmunization, SecondaryMaleMiddle Aged

Funding

  • Pfizer
Citations
15,281
FWCI
311.19
field-weighted impact
References
8
Percentile
100%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.